Virtual reality vision testing for patients with age-related macular degeneration
Virtual Reality (VR) Based Vision Test in Subjects With Age-related Macular Degeneration (AMD)
This study tests whether virtual reality can help people with age-related macular degeneration better understand their vision problems by comparing it to traditional eye tests.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 50 Years to 105 Years |
| Sex | All |
| Sponsor | Augenklinik Zurich West Academic / other |
| Locations | 1 site (Zürich, Zurich) |
| Trial ID | NCT06241625 on ClinicalTrials.gov |
What this trial studies
This study evaluates the usability, tolerability, and repeatability of virtual reality (VR) tasks designed to assess contrast sensitivity in patients with age-related macular degeneration (AMD). Researchers aim to bridge the gap between existing functional measures and AMD lesions by using VR tools. The primary goal is to correlate the VR-based contrast sensitivity function metrics with conventional clinical measurements of retinal anatomy and visual function. Participants will undergo VR testing and quality optical coherence tomography imaging to gather comprehensive data.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with AMD who have a Snellen BCVA score of 20/100 or better.
Not a fit: Patients with significant oculomotor impairments, neurological conditions, or those unwilling to use a VR headset may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a more effective and engaging method for assessing vision in patients with AMD.
How similar studies have performed: While the use of VR in clinical assessments is emerging, this specific application in AMD is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects ≥18 years of age diagnosed with AMD 2. Subject Snellen BCVA score is 20/100 or better 3. Ability to undergo quality optical coherence tomography (OCT) imaging 4. Willing and able to give written informed consent Exclusion Criteria: 1. Unwilling to use headset 2. Previous negative experience with a VR headset (eg, motion sickness, discomfort) 3. Any known oculomotor impairment that would impact the ability of the subject to perform the tasks (eg, nystagmus, proptosis, apraxia of eyelid opening) 4. Any manifest neurological or cognitive condition that would impair the subject's understanding or performance on the test (eg, Alzheimer's disease, Parkinson's disease) 5. Any physical limitations that would prohibit the use of the VR headset (eg, neck problems)
Where this trial is running
Zürich, Zurich
- Augenklinik Zurich West — Zürich, Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Stephan Michels, MD — Augenklinik Zurich West
- Study coordinator: Stephan Michels, MD
- Email: info@augenklinik-zh.ch
- Phone: +414454517
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.